https://www.selleckchem.com/products/phtpp.html
The median and 5-year DFS Kaplan-Meier estimates in RECUR corresponding to each trial eligibility criteria were not reached and 69.6% for RAMPART; not reached and 64.5% for PROSPER; 109.3 months (95% confidence interval [CI], 83.9-134.6 months) and 57% for CheckMate-914; 75.8 months (95% CI, 52.7-98.8 months) and 54.3% for Keynote-564; and 43.6 months (95% CI, 30.8-56.4 months) and 45% for IMMotion-010. Our analysis may be limited by the retrospective design. RECUR provides estimated DFS and OS benchmarks for placebo arms of adjuvant chec
Like
Comment
Share
